• Reference Citation Analysis
  • v
  • v
  • Find an Article
Download
Number Select Citation Analysis
1 Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev 2022;110:102460. [DOI: 10.1016/j.ctrv.2022.102460] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
2 Iyer KK, van Erp NP, Tauriello DV, Verheul HM, Poel D. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treat Rev 2022;110:102466. [DOI: 10.1016/j.ctrv.2022.102466] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
3 Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261-73. [DOI: 10.1016/s1470-2045(22)00541-1] [Cited by in Crossref: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
4 Sobash PT, Ullah A, Karim NA. Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors. Cancers (Basel) 2022;14:4730. [DOI: 10.3390/cancers14194730] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
5 Shen X, Wang X, Lu X, Zhao Y, Guan W. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation. Front Oncol 2022;12:967071. [DOI: 10.3389/fonc.2022.967071] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
6 Nie C, Lv H, Chen B, Xu W, Wang J, Liu Y, Wang S, Zhao J, He Y, Chen X. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study. Front Oncol 2022;12:917353. [DOI: 10.3389/fonc.2022.917353] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
7 Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol 2022. [PMID: 36151307 DOI: 10.1038/s41571-022-00682-6] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
8 Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2022:S0889-8588(22)00073-9. [PMID: 36154786 DOI: 10.1016/j.hoc.2022.07.005] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
9 Feng A, Guo J, Gao S, Kou F, Liu S, Liu P, Chen H, Wang X, Xu H, Cao G, Zhu X. A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases. Front Oncol 2022;12:913017. [DOI: 10.3389/fonc.2022.913017] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
10 Gonzáles-Yovera JG, Roseboom PJ, Concepción-Zavaleta M, Gutiérrez-Córdova I, Plasencia-Dueñas E, Quispe-Flores M, Ramos-Yataco A, Alcalde-Loyola C, Massucco-Revoredo F, Paz-Ibarra J, Concepción-Urteaga L. Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. World J Methodol 2022; 12(5): 381-391 [DOI: 10.5662/wjm.v12.i5.381] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
11 D’onofrio R, Caputo F, Prampolini F, Spallanzani A, Gelsomino F, Bettelli S, Manfredini S, Reggiani Bonetti L, Carotenuto P, Bocconi A, Dominici M, Luppi G, Salati M. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice. Tumori. [DOI: 10.1177/03008916221122554] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
12 Wong NACS, Garcia-Petit C, Dangoor A, Andrew N. A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib. Cancer Genet 2022;268-269:46-54. [PMID: 36155382 DOI: 10.1016/j.cancergen.2022.09.002] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
13 Li JP, Liu YJ, Zeng SH, Gao HJ, Chen YG, Zou X. Identification of COX4I2 as a hypoxia-associated gene acting through FGF1 to promote EMT and angiogenesis in CRC. Cell Mol Biol Lett 2022;27:76. [PMID: 36064310 DOI: 10.1186/s11658-022-00380-2] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
14 Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu-Spinu II, Greabu M, Ripszky Totan A, Jinga M. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. Int J Mol Sci 2022;23:10132. [PMID: 36077529 DOI: 10.3390/ijms231710132] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
15 Takahashi H, Yaegashi Y, Saito Y, Nihei S, Tairabune T, Ujiie H, Asaka J, Kudo K. Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. J Pharm Health Care Sci 2022;8:22. [PMID: 36045384 DOI: 10.1186/s40780-022-00253-y] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
16 Cho SK, Bekaii-saab T, Kavati A, Babajanyan S, Hocum B, Barzi A. Value-based analysis of therapies in refractory metastatic colorectal cancer in US. Clin Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.09.003] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
17 Waterman M, Lee RM, Carter JC, Garland SN. Orthorexia symptoms and disordered eating behaviors in young women with cancer. Eat Behav 2022. [DOI: 10.1016/j.eatbeh.2022.101672] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
18 Osumi H, Ishizuka N, Takashima A, Kumekawa Y, Nakano D, Shiozawa M, Denda T, Sawada R, Ouchi K, Wakatsuki T, Narikazu B, Kato K, Yamaguchi K, Shinozaki E. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ Open 2022;12:e063071. [DOI: 10.1136/bmjopen-2022-063071] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
19 Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med 2022;14:101. [PMID: 36045401 DOI: 10.1186/s13073-022-01102-1] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
20 Özet A, Dane F, Aykan NF, Yalçın Ş, Evrensel T, Özkan M, Karabulut B, Ormeci MN, Atasev O, Vidot L, Çiçin İ. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncol 2022. [PMID: 36040321 DOI: 10.2217/fon-2022-0455] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
21 Yang Q, Zhu L, Liu H, Zheng Q, Li L. Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer. Front Pharmacol 2022;13:806728. [DOI: 10.3389/fphar.2022.806728] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
22 Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04316-3] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
23 Spolverato G, Capelli G, Mari V, Lorenzoni G, Gregori D, Poultsides G, Fields RC, Weber SM, Votanopoulos K, Cho CS, He J, Maithel SK, Pucciarelli S, Pawlik TM. Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma. Ann Surg Oncol 2022. [PMID: 36018525 DOI: 10.1245/s10434-022-12434-y] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
24 He F, Xie L, Sun X, Xu J, Li Y, Liu R, Sun K, Shen D, Gu J, Ji T, Guo W. A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High-Grade Bone Sarcomas: A Multicenter Study. Orthop Surg 2022. [PMID: 36017768 DOI: 10.1111/os.13469] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
25 Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA, Johnson CH. Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Front Mol Biosci 2022;9:958666. [DOI: 10.3389/fmolb.2022.958666] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
26 Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 2022:oyac161. [PMID: 35983951 DOI: 10.1093/oncolo/oyac161] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
27 Ciardiello D, Chiarazzo C, Famiglietti V, Damato A, Pinto C, Zampino MG, Castellano G, Gervaso L, Zaniboni A, Oneda E, Rapisardi S, Bordonaro R, Zichi C, De Vita F, Di Maio M, Parisi A, Giampieri R, Berardi R, Lavacchi D, Antonuzzo L, Tamburini E, Maiorano BA, Parrella P, Latiano TP, Normanno N, De Stefano A, Avallone A, Martini G, Napolitano S, Troiani T, Martinelli E, Ciardiello F, De Vita F, Maiello E. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open 2022;7:100567. [PMID: 35994791 DOI: 10.1016/j.esmoop.2022.100567] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
28 Rausch C, Schwicht C, Doedens D, Forstpointner R, Westphalen CB, Heinemann V. Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series. Eur J Cancer 2022;174:37-9. [PMID: 35970034 DOI: 10.1016/j.ejca.2022.07.013] [Cited by in Crossref: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
29 Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study. Acta Oncol 2022;:1-8. [PMID: 35943168 DOI: 10.1080/0284186X.2022.2098053] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
30 Agarwal P, Mohamed A. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Curr Treat Options Oncol 2022. [PMID: 35939200 DOI: 10.1007/s11864-022-00998-6] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
31 Zhao Z, Bian J, Zhang J, Zhang T, Lu X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. Front Oncol 2022;12:843707. [DOI: 10.3389/fonc.2022.843707] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
32 Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 2022;10:e005332. [PMID: 36007963 DOI: 10.1136/jitc-2022-005332] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
33 Li N, Zheng H, Yu Q, Chen F, Su X, Qiu X. Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. J Int Med Res 2022;50:030006052211152. [DOI: 10.1177/03000605221115251] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
34 Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 2022. [PMID: 35915157 DOI: 10.1038/s41591-022-01886-0] [Cited by in Crossref: 3] [Cited by in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
35 Kairey L, Leech B, El-Assaad F, Bugarcic A, Dawson D, Lauche R. The effects of kefir consumption on human health: a systematic review of randomized controlled trials. Nutr Rev 2022:nuac054. [PMID: 35913411 DOI: 10.1093/nutrit/nuac054] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
36 Torres-jiménez J, Esteban-villarrubia J, Ferreiro-monteagudo R. Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. Cancers (Basel) 2022;14:3718. [DOI: 10.3390/cancers14153718] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
37 Damato A, Rotolo M, Caputo F, Borghi E, Iachetta F, Pinto C. New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. Life (Basel) 2022;12:1137. [PMID: 36013315 DOI: 10.3390/life12081137] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
38 Sharma R, Slater S, Evans J, Martinez M, Ward C, Izadi H, Wernig F, Thomas R. ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs). BMC Cancer 2022;22:800. [PMID: 35858849 DOI: 10.1186/s12885-022-09859-9] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
39 Michels RE, Arteaga CH, Peters ML, Kapiteijn E, Van Herpen CML, Krol M. Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers. Appl Health Econ Health Policy 2022. [PMID: 35843997 DOI: 10.1007/s40258-022-00740-1] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
40 Bignucolo A, Scarabel L, Toffoli G, Cecchin E, De Mattia E. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Rev Clin Pharmacol 2022. [PMID: 35829762 DOI: 10.1080/17512433.2022.2101447] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
41 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
42 Ros J, Saoudi N, Baraibar I, Salva F, Tabernero J, Elez E. Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. Therap Adv Gastroenterol 2022;15:17562848221110644. [PMID: 35812780 DOI: 10.1177/17562848221110644] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
43 Gou M, Qian N, Zhang Y, Yan H, Si H, Wang Z, Dai G. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. Front Oncol 2022;12:851756. [DOI: 10.3389/fonc.2022.851756] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
44 Arora R, Sharma S, Kumar B. Colorectal cancer: risk factors and potential of dietary probiotics in its prevention. Proc Indian Natl Sci Acad . [DOI: 10.1007/s43538-022-00083-4] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
45 Kourie HR, Ibnshamsah F, Zouein J, Naim N, Abbasi S, Allahloubi N, Al-naqqash M, Alolayan A, Alshehri A, Bitar N, Bounedjar A, Farsi AA, Shamsi HE, Ghali R, Jaafar H, Larbaoui B, Mahrous M, Mrabti H, Nweir AR, Oukkal M, Rasul K, Razavi M, Turfa R, Khatib S, Shamseddine A. The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future Oncol. [DOI: 10.2217/fon-2022-0282] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
46 Stroes CI, Schokker S, Khurshed M, van der Woude SO, Mathôt RA, Slingerland M, de Vos-Geelen J, Zucchetti M, Matteo C, van Dijk E, Ylstra B, Thijssen V, Derks S, Godefa T, Dijksterhuis W, Breimer GE, van Delden OM, Verhoeven RH, Meijer SL, Bijlsma MF, van Laarhoven HW. A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Ther Adv Med Oncol 2022;14:17588359221109196. [PMID: 35782751 DOI: 10.1177/17588359221109196] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
47 Siswara HN, Erwanto Y, Suryanto E. Study of Meat Species Adulteration in Indonesian Commercial Beef Meatballs Related to Halal Law Implementation. Front Sustain Food Syst 2022;6:882031. [DOI: 10.3389/fsufs.2022.882031] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
48 Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, Havekes B, Hofland J, Kerkhofs TMA, Klümpen HJ, Latten-Jansen LM, Speel EM, Verburg FA, Walenkamp AME, Geurts SME, de Vos-Geelen J. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer 2022;172:252-63. [PMID: 35803176 DOI: 10.1016/j.ejca.2022.06.003] [Cited by in Crossref: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]
49 Ibrahem S, Ahmed H, Zangana S. Trends in colorectal cancer in Iraq over two decades: incidence, mortality, topography and morphology. Ann Saudi Med 2022;42:252-61. [PMID: 35933610 DOI: 10.5144/0256-4947.2022.252] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
50 Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Dustin DJ, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F, Janku F. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol 2022;6:e2100512. [PMID: 35834760 DOI: 10.1200/PO.21.00512] [Cited by in Crossref: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text]  Open
PrevPage 1 of 48 123454748Next
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA